
Feature|Articles|September 23, 2025
Testing a Promising Remyelinating Agent for Relapsing-Remitting Multiple Sclerosis: The VISTA Trial
Author(s)Isabella Ciccone, MPH
A new trial evaluates PIPE-307, a drug targeting M1 receptors, aiming to promote remyelination in relapsing-remitting multiple sclerosis patients.
Advertisement
Advertisement
Relapsing-remitting multiple sclerosis (RRMS) is the most prevalent form of multiple sclerosis (MS). A defining feature of all MS types is the presence of demyelinating lesions in the brain and spinal cord. In healthy neurons, myelin, a specialized extension of the oligodendrocyte plasma membrane, acts as an insulator, enabling rapid and efficient conduction of electrical signals along the axon. In demyelinating conditions such as MS, the loss of myelin slows signal transmission and can ultimately result in permanent impairment of neuronal function.1
Related to this article

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

In a real-world cohort, tenecteplase before thrombectomy was associated with lower mortality and fewer new speech and movement deficits than alteplase, without an increase in symptomatic intracranial hemorrhage.
Advertisement
Advertisement


